Eliaz Therapeutics has started a Regulation Crowdfunding round to fund GLP safety studies and first-in-human trials of XGal-3, an apheresis device targeting Galectin-3 to treat sepsis. The device has FDA Breakthrough Device Designation and aims to address sepsis by removing a key inflammatory protein, potentially improving survival. With $8M raised and strong preclinical data, the company plans to expand clinical development and explore broader applications for Galectin-3-related diseases.
Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...
Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...
Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...
Oppenheimer lowered Nike's price target to $52 from a higher level, reflecting concerns over falling sales and macroeconomic challenges. Despite Nike's stock trading near its 52-week low around $35.35, the new target implies a potential 44.85% upside...
Stifel Financial upgraded Microsoft from Hold to Buy, raising its price target to $575 due to strong growth prospects in Azure cloud services and Microsoft 365 Copilot. The analyst highlighted Azure's 43% year-over-year revenue growth and over 30 mil...
